Skip to main content
Oncolys BioPharma Inc. logo

Oncolys BioPharma Inc. — Investor Relations & Filings

Ticker · 4588 ISIN · JP3202170001 T Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2026-03-25 Regulatory Filings
Country JP Japan
Listing T 4588

About Oncolys BioPharma Inc.

https://www.oncolys.com/en/

Oncolys BioPharma Inc. is a biopharmaceutical company focused on the research and development of breakthrough therapies and diagnostics for cancer. The company's core technology is oncolytic virotherapy, which utilizes viruses to selectively target and destroy cancer cells. Its development pipeline addresses multiple stages of cancer care, spanning from early detection and prognostic testing to loco-regional and systemic treatments. The company aims to develop innovative and effective drugs to meet the needs of patients and healthcare providers in the field of oncology.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is a Japanese "確認書" (confirmation letter) submitted under the Financial Instruments and Exchange Act (金商法第24条の４の２第１項) to the Kanto Local Finance Bureau. It confirms the accuracy of the 22nd period securities report (有価証券報告書) for the year ending December 31, 2025. This is a formal regulatory filing with the financial authority rather than an annual report itself or an announcement of its publication. It does not fit the categories for Annual Report (10-K), Interim Report, Earnings Release, etc., and is instead a miscellaneous regulatory submission. Thus, it falls under the fallback “Regulatory Filings” category (RNS).
2026-03-25 Japanese
有価証券報告書－第22期(2025/01/01－2025/12/31)
Annual Report Classification · 1% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, business history, and management information for the fiscal year ending December 31, 2025. It is a comprehensive annual filing, not an announcement or a summary. FY 2025
2026-03-25 Japanese
確認書
Regulatory Filings
2025-08-08 Japanese
半期報告書－第22期(2025/01/01－2025/12/31)
Interim / Quarterly Report
2025-08-08 Japanese
有価証券届出書（参照方式）
Capital/Financing Update Classification · 1% confidence The document header explicitly states "【提出書類】有価証券届出書" (Filing Document: Securities Registration Statement) and details the filing date (2025年７月18日), the recipient (関東財務局長 - Kanto Local Finance Bureau Director), and the security being offered: "新株予約権証券 (行使価額修正条項付新株予約権付社債券等)" (Stock Acquisition Rights Certificate (Bonds with Stock Acquisition Rights with Exercise Price Adjustment Clause)). This structure and content are characteristic of a Japanese regulatory filing related to the issuance of securities, specifically stock acquisition rights (warrants/options) attached to bonds, which is a form of capital raising/financing activity. While it involves capital/financing (CAP), the document itself is a formal registration statement filed with a regulatory body (Financial Services Agency equivalent in Japan). In the provided classification scheme, there isn't a direct code for a general 'Securities Registration Statement' (like an S-1 or F-1 in the US context). However, the core purpose is related to raising capital through the issuance of new securities (stock acquisition rights). Given the options, 'Capital/Financing Update' (CAP) is the most relevant category describing the *activity*, but the document type is a formal regulatory filing. Reviewing the definitions: - CAP (Capital/Financing Update): Updates on company fundraising, financing activities, or capital structure changes. This fits the *purpose*. - RNS (Regulatory Filings): General regulatory announcements and fallback. This fits the *nature* of the document. Since this is a detailed, multi-page registration statement detailing the terms of the offering (募集要項), it is a primary regulatory disclosure document concerning financing. In many classification systems, detailed registration statements are often grouped under the primary activity or as a specific regulatory filing type. Given the highly specific nature of the other codes, and the fact that this is a formal filing detailing a capital raise, 'CAP' captures the economic substance better than the generic 'RNS', unless 'RNS' is intended for all non-standard disclosures. Since the document is a comprehensive registration statement for a new security issuance, 'CAP' is the strongest fit for the *event* being disclosed, even though it is filed as a regulatory document. However, looking closely at the structure, it is a formal filing submitted to the Kanto Local Finance Bureau, which strongly suggests a regulatory filing category. If we must choose between the specific activity (CAP) and the document format (Regulatory Filing), and considering that detailed registration statements are often distinct from simple 'updates', 'RNS' (Regulatory Filings) serves as a strong candidate for formal, comprehensive regulatory disclosures that don't fit 10-K, AR, or ER. Given the context of Japanese filings, this is a 'Yuka Shoken Todoke Sho' (Securities Registration Statement), which is a core regulatory disclosure. I will classify it as CAP because the document's entire focus is the terms of the capital raise, which is the most specific description available for this type of event, even if it is a formal filing.
2025-07-18 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 that it is being submitted because resolutions were passed at the '第21回定時株主総会' (21st Annual General Meeting) held on March 27, 2025. Section 2 details the resolutions, which include the election of directors and auditors, and a capital reduction/surplus appropriation. Section 3 provides the voting results for these resolutions. This content—reporting the results of an Annual General Meeting (AGM)—directly corresponds to the definition of 'AGM Information' (AGM-R). Although it is a formal filing ('臨時報告書'), the core content is the outcome of the AGM, making AGM-R the most specific classification over a general regulatory filing (RNS). The document length is short (2750 chars), but it is the report itself, not an announcement of a report, as it contains the detailed voting results.
2025-03-31 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.